AcquisitionsMay 22, 2026, 04:22 PM
Centessa-Lilly Acquisition HSR Waiting Period Expires
AI Summary
Centessa Pharmaceuticals plc announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its acquisition by Eli Lilly and Company expired on May 21, 2026. This satisfies one of the conditions required for the closing of the acquisition, which is structured as a court-sanctioned scheme of arrangement. The transaction remains subject to other customary closing conditions, including approval from Centessa's shareholders and sanction by the High Court of Justice of England and Wales.
Key Highlights
- The Hart-Scott-Rodino Act waiting period for Centessa's acquisition by Eli Lilly expired on May 21, 2026.
- Expiration of the HSR Act waiting period satisfies one condition for the acquisition's closing.
- The acquisition is being conducted via a court-sanctioned scheme of arrangement.
- Remaining closing conditions include Centessa shareholder approval and High Court sanction.
- The Transaction Agreement between Centessa and Lilly was dated March 31, 2026.
- Centessa Pharmaceuticals is not subject to the UK Takeover Code.
Price Impact
More from CNTA